# US 9,040,295 B2 · Anti-human α9 integrin antibody and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 9,040,295 B2
- Document ID: US9040295B2
- Status: Granted
- Kind: B2
- Application number: 13/742,680
- Filed: 2013-01-16
- Published: 2013-05-16
- Granted: 2015-05-26
- Earliest claimed: 2013-01-16
- Assignees: Gene Techno Science Co., Ltd.
- Applicants: Gene Techno Science Co., Ltd.
- Inventors: Shigeyuki Kon; Toshimitsu Uede
- Web page: https://patentgrep.com/patent/US9040295B2

## CPC

- C07K 16/2839: {against the integrin superfamily}
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 35/00: Antineoplastic agents
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- G01N 2333/70546: Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention relates to an anti-human α9 integrin antibody. More particularly, the present invention relates to: a monoclonal antibody, a chimeric antibody, a humanized antibody and a human antibody that specifically recognize human α9 integrin; a hybridoma cell that produces the monoclonal antibody; a method for producing the monoclonal antibody; a method for producing the hybridoma cell; a therapeutic agent comprising the anti-human α9 integrin antibody; a diagnostic agent comprising the human α9 integrin antibody; and a method for screening for a compound that inhibits the activity of human α9 integrin.

## Claims

### Claim 1

A therapeutic agent for a cancer rheumatoid arthritis, osteoarthritis or hepatitis, comprising as an active component an anti-human α9 integrin antibody comprising the amino acid sequences of SEQ ID NOS:1, 3, and 5 as CDRH1, CDRH2, and CDRH3, respectively, of the complementary determining region of the heavy chain (CDRH), and the amino acid sequences of SEQ ID NOS: 7, 9 and 11 as CDRL1, CDRL2, and CDRL3, respectively, of the complementary determining region of the light chain (CDRL).

### Claim 2

A therapeutic agent for a cancer, rheumatoid arthritis, osteoarthritis or hepatitis, comprising as active components an anti-human α4 integrin antibody and an anti-human α9 integrin antibody comprising the amino acid sequences represented by SEQ ID NOS:1, 3, and 5 as CDRH1, CDRH2, and CDRH3, respectively, of the complementary determining region of the heavy chain (CDRH), and the amino acid sequences of SEQ ID NOS: 7, 9 and 11 as CDRL1, CDRL2, and CDRL3, respectively, of the complementary determining region of the light chain (CDRL).

### Claim 3

A diagnostic agent for a cancer, rheumatoid arthritis, osteoarthritis or hepatitis, comprising as an active component an anti-human α9 integrin antibody comprising the amino acid sequences of SEQ ID NOS:1, 3, and 5 as CDRH1, CDRH2, and CDRH3, respectively, of the complementary determining region of the heavy chain (CDRH), and the amino acid sequences of SEQ ID NOS: 7, 9 and 11 as CDRL1, CDRL2, and CDRL3, respectively, of the complementary determining region of the light chain (CDRL).

### Claim 4

A pharmaceutical composition comprising as an active component an anti-human α9 integrin antibody comprising the amino acid sequences of SEQ ID NOS:1, 3, and 5 as CDRH1, CDRH2, and CDRH3, respectively, of the complementary determining region of the heavy chain (CDRH), and the amino acid sequences of SEQ ID NOS: 7, 9 and 11 as CDRL1, CDRL2, and CDRL3, respectively, of the complementary determining region of the light chain (CDRL) and a pharmacologically-acceptable carrier, diluent or excipient.

### Claim 5

A method for treating an ECM-related disease, said method comprising administering to a subject in need thereof an anti-human α9 integrin antibody comprising the amino acid sequences of SEQ ID NOS:1, 3, and 5 as CDRH1, CDRH2, and CDRH3, respectively, of the complementary determining region of the heavy chain (CDRH), and the amino acid sequences of SEQ ID NOS: 7, 9 and 11 as CDRL1, CDRL2, and CDRL3, respectively, of the complementary determining region of the light chain (CDRL), wherein said ECM-related disease is selected from the group consisting of rheumatoid arthritis, osteoarthritis and hepatitis.